- Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
- Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Key statistics
On Thursday, Gritstone bio Inc (GRTS:NSQ) closed at 0.87, 29.54% above the 52 week low of 0.6716 set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8844 |
---|---|
High | 0.8982 |
Low | 0.8319 |
Bid | 0.8602 |
Offer | 0.88 |
Previous close | 0.8737 |
Average volume | 1.82m |
---|---|
Shares outstanding | 107.13m |
Free float | 104.69m |
P/E (TTM) | -- |
Market cap | 93.60m USD |
EPS (TTM) | -1.55 USD |
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼